ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights GlobeNewswire August 13, 2025 U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer's Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date […]

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series GlobeNewswire August 13, 2025 NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in

Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited) GlobeNewswire August 13, 2025 Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) — Sanara MedTech Inc.

Inotiv, Inc. to Participate in Three Investor Conferences in September 2025 GlobeNewswire August 13, 2025 WEST LAFAYETTE, Ind., Aug. 13, 2025 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services,

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy(R) (epinephrine nasal spray) GlobeNewswire August 13, 2025 $15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated

Lantronix to Report Fiscal 2025 Fourth Quarter Results on Aug. 27, 2025 GlobeNewswire August 13, 2025 IRVINE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (the “Company”) (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions enabling Edge AI Intelligence, today announced it will release financial results from its fiscal 2025 fourth

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results GlobeNewswire August 13, 2025 More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC) Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025 Conference call today

Greenbacker sells 51 MW distributed solar portfolio, advancing strategic focus on scaled clean energy projects GlobeNewswire August 13, 2025 NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) — Greenbacker, an energy transition-focused investment manager and independent power producer, today announced the sale of a 51.2 MW portfolio of 64 operating solar assets to CleanCapital, a leading

Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights GlobeNewswire August 13, 2025 – Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – — Additional data from the ongoing Phase 2

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights GlobeNewswire August 13, 2025 Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to Fund Operations into